scispace - formally typeset
P

Peter Trenkwalder

Researcher at Ludwig Maximilian University of Munich

Publications -  63
Citations -  3571

Peter Trenkwalder is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Blood pressure & Candesartan. The author has an hindex of 21, co-authored 61 publications receiving 3400 citations. Previous affiliations of Peter Trenkwalder include AstraZeneca.

Papers
More filters
Journal ArticleDOI

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

TL;DR: In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.
Journal ArticleDOI

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment.

Goodarz Danaei, +340 more
TL;DR: In this paper, the authors used data for exposure to risk factors by country, age group, and sex from pooled analyses of population-based health surveys and obtained relative risks for the eff ects of risk factors on cause-specifi c mortality from meta-analyses of large prospective studies.
Journal ArticleDOI

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE)

TL;DR: In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihyertensive treatment, despite little difference in blood pressure reduction.